Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $15,803.20 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 581 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $27.20, for a total transaction of $15,803.20. Following the completion of the transaction, the chief financial officer now owns 122,766 shares in the company, valued at $3,339,235.20. This represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, November 12th, Troy Wichterman sold 147 shares of BioLife Solutions stock. The shares were sold at an average price of $26.19, for a total transaction of $3,849.93.
• On Wednesday, October 30th, Troy Wichterman sold 894 shares of BioLife Solutions stock. The shares were sold at an average price of $23.15, for a total transaction of $20,696.10.
• On Monday, September 16th, Troy Wichterman sold 611 shares of BioLife Solutions stock. The shares were sold at an average price of $25.12, for a total transaction of $15,348.32.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS opened at $27.47 on Monday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average price of $24.23 and a 200 day moving average price of $23.24. BioLife Solutions, Inc. has a 52 week low of $11.91 and a 52 week high of $28.88. The company has a market cap of $1.27 billion, a P/E ratio of -25.92 and a beta of 1.88.

Analyst Ratings Changes

Several brokerages have commented on BLFS. Craig Hallum increased their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Northland Securities lifted their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. HC Wainwright decreased their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Finally, TD Cowen boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.50.

Institutional Trading of BioLife Solutions

A number of institutional investors have recently modified their holdings of the business. Stifel Financial Corp boosted its position in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in BioLife Solutions by 4.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock valued at $392,000 after purchasing an additional 700 shares in the last quarter. GAMMA Investing LLC increased its stake in BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 748 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in BioLife Solutions by 5.8% during the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock worth $296,000 after purchasing an additional 753 shares in the last quarter. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in shares of BioLife Solutions in the 3rd quarter worth about $28,000. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.